Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety;Cannabinoide in der palliativen Versorgung: Systematische Übersicht und Metaanalyse der Wirksamkeit, Verträglichkeit und Sicherheit

Schmerz

Volumn 30, Issue 1, 2016, Pages 25-36

  Mucke M ^a,b   Carter, C ^a   Cuhls, H ^a   Pruss M ^c   Radbruch, L ^a,d   Hauser W ^e,f  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Malteser Hospital Bonn/Rhein Sieg Bonn   (Germany)

^e KLINIKUM SAARBRÜCKEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer disease; HIV; Neoplasms; Palliative medicine; Symptom control

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; MEGESTROL ACETATE; PLACEBO;

ALZHEIMER DISEASE; ANOREXIA; APPETITE DISORDER; ARTICLE; ATTRIBUTABLE RISK; CALORIC INTAKE; CANCER PAIN; CANCER RESEARCH; COCHRANE LIBRARY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PSYCHOSIS; PSYCINFO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCOPUS; SLEEP DISORDER; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; WASTING SYNDROME; WEIGHT CHANGE; WEIGHT GAIN; CLINICAL TRIAL (TOPIC); PROCEDURES; TREATMENT OUTCOME;

CANNABINOIDS; CLINICAL TRIALS AS TOPIC; HUMANS; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 84958654892     PISSN: 0932433X     EISSN: 14322129     Source Type: Journal    
DOI: 10.1007/s00482-015-0085-2     Document Type: Article

References (32)

1. Ablin J, St. Marie P, Häuser W et al (2016) Medical use of cannabis products. Lessons to be learned from Israel and Canada. Schmerz 30 (im Druck)
2. Abrams DI, Hilton JF, Leiser RJ et al (2003) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139:258–266
3. Beal JE, Olson R, Laubenstein L et al (1995) Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89–97
4. Beal JE, Olson R, Lefkowitz L et al (1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7–14. doi:10.1016/S0885-3924(97)00038-9
5. Bedi G, Foltin RW, Gunderson EW et al (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. 212:675–686. doi:10.1007/s00213-010-1995-4
6. Belendiuk KA, Baldini LL, Bonn-Miller MO (2015) Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract 10:1–10. doi:10.1186/s13722-015-0032-7
7. Brisbois TD, de Kock IH, Watanabe SM et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22:2086–2093. doi:10.1093/annonc/mdq727
8. Gross H, Ebert MH, Faden VB et al (1983) A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 3:165–171
9. Grotenhermen F, Müller-Vahl K (2012) The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 109:495–501. doi:10.3238/arztebl.2012.0495
10. Haney M, Gunderson EW, Rabkin J et al (2007) Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J Acquir Immune Defic Syndr 45:545–554. doi:10.1097/QAI.0b013e31811ed205
11. Haney M, Rabkin J, Gunderson E, Foltin RW (2005) Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 181:170–178. doi:10.1007/s00213-005-2242-2
12. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. http://handbook.cochrane.org/. Zugegriffen: 10. Oktober 2015
13. Jatoi A, Windschitl HE, Loprinzi CL et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20:567–573
14. Johnson JR, Burnell-Nugent M, Lossignol D et al (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167–179. doi:10.1016/j.jpainsymman.2009.06.008
15. Jordhøy MS, Kaasa S, Fayers P et al (1999) Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med 13:299–310
16. Kaasa S, Hjermstad MJ, Loge JH (2006) Methodological and structural challenges in palliative care research: how have we fared in the last decades? Palliat Med 20:727–734. doi:10.1177/0269216306072620
17. Lutge EE, Gray A, Siegfried N (2013) The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 4:CD005175
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3:e123–e130
19. Noyes R, Brunk SF, Avery DA, Canter AC (1975) The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18:84–89
20. Portenoy RK, Ganae-Motan ED, Allende S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13:438–449. doi:10.1016/j.jpain.2012.01.003
21. Regelson W, Butler JR, Schulz J (1976) Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S (Hrsg) Pharmacology of Marihuana. Raven Press, New York, S 763–775
22. Sigurdardottir KR, Haugen DF, van der Rijt CCD et al (2010) Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop. Eur J Cancer 46:1815–1822. doi:10.1016/j.ejca.2010.03.012
23. Staquet M, Gantt C, Machin D (1978) Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23:397–401
24. Strasser F (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394–3400. doi:10.1200/JCO.2005.05.1847
25. Struwe M, Kaempfer SH, Geiger CJ et al (1993) Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827–831
26. Tait RJ, Caldicott D, Mountain D et al (2015) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1–13. doi:10.3109/15563650.2015.1110590
27. Timpone JG, Wright DJ, Li N et al (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 13:305–315. doi:10.1089/aid.1997.13.305
28. Volicer L, Stelly M, Morris J et al (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 12:913–919. doi:10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D
29. Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456. doi:10.1001/jama.2015.6358
30. Zadikoff C, Wadia PM, Miyasaki J et al (2011) Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial. Basal Ganglia 1:91–95. doi:10.1016/j.baga.2011.04.002
31. Zhang MW, Ho RCM (2015) The cannabis dilemma: a review of its associated risks and clinical efficacy. J Addict 2015:707596. doi:10.1155/2015/707596
32. Zutt M, Hänßle H, Emmert S et al (2006) Dronabinol zur supportiven Therapie metastasierter maligner Melanome mit Lebermetastasen. Hautarzt 57:423–427. doi:10.1007/s00105-005-1063-x